Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 3-15 , January 2012

The multi-disciplinary management of high-risk prostate cancer

  • Jonathan C. Picard, M.D.

      Affiliations

    • Department of Urology, Medical University of South Carolina, Charleston, SC 29425, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-843-792-4286; fax: +1-843-792-8523
    • ,
  • Ali-Reza Golshayan, M.D.

      Affiliations

    • Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • David T. Marshall, M.D., M.S.

      Affiliations

    • Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • Krisha J. Opfermann, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • Thomas E. Keane, M.B.B.Ch., F.R.C.S.I., F.A.C.S.

      Affiliations

    • Department of Urology, Medical University of South Carolina, Charleston, SC 29425, USA

Received 30 June 2009 ,Revised 2 September 2009 ,Accepted 3 September 2009.

References 

  1. Jemal A , Thun MJ , Ries LA , et al.  Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control . J Natl Cancer Inst . 2008;100:1672–1694
  2. Thompson I , Thrasher JB , Aus G , et al.  Guideline for the management of clinically localized prostate cancer: 2007 update . J Urol . 2007;177:2106–2131
  3. Nguyen CT , Reuther AM , Stephenson AJ , et al.  The specific definition of high risk prostate cancer has minimal impact in biochemical relapse-free survival . J Urol . 2009;181:75–80
  4. D'Amico AV , Cote K , Loffredo M , et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer . J Clin Oncol . 2002;20:4567–4573
  5. D'Amico AV , Moul J , Carroll PR , et al.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era . J Clin Oncol . 2003;21:2163–2172
  6. D'Amico AV , Whittington R , Malkowicz SB , et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer . JAMA . 1998;280:969–974
  7. Roehl KA , Han M , Ramos CG , et al.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results . J Urol . 2004;172:910–914
  8. Han M , Partin AW , Pound CR , et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy (The 15-year Johns Hopkins experience) . Urol Clin North Am . 2001;28:555–565
  9. Bianco FJ , Scardino PT , Eastham JA . Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”) . Urology . 2005;66(5 Suppl):83–94
  10. Freedland  , Partin AW , Humphreys EB , et al.  Radical prostatectomy for clinical stage T3a disease . Cancer . 2007;109:1273–1278
  11. Ward JF , Slezak JM , Blute ML , et al.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome . BJU Int . 2005;95:751–756
  12. Carver BS , Bianco FJ , Scardino PT , et al.  Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer . J Urol . 2006;176:564–568
  13. Hsu CY , Joniau S , Oyen R , et al.  Outcome of surgery for clinical unilateral T3a prostate cancer: A single-institution experience . Eur Urol . 2007;51:121–129
  14. Yossepowitch O , Eggener SE , Bianco FJ , et al.  Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods . J Urol . 2007;178:493–499
  15. Powell IJ , Tangen CM , Miller GJ , et al.  Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109 . J Urol . 2002;168:2016–2019
  16. Dalkin BL , Ahmann FR , Nagle R , et al.  Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer . J Urol . 1996;155:1357–1360
  17. Soloway MS , Pareek K , Sharifi R , et al.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results . J Urol . 2002;167:112–116
  18. Namiki K , Rosser CJ . Neoadjuvant therapy and prostate cancer: What a urologist should know . Curr Opin Urol . 2007;17:188–193
  19. Kumar S , Shelley M , Harrison C , et al.   Neoadjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer . Cochrane Database Syst Rev. 2006;4: CD006019
  20. Messing EM , Manola J , Yao J , et al.  Immediate vs. deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy . Lancet Oncol . 2006;7:472–479
  21. Anscher MS , Robertson CN , Prosnitz R . Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: 10-year update . Int J Radiat Oncol Biol Phys . 1995;33:37–43
  22. Anscher MS , Prosnitz LR . Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule . J Urol . 1987;138:1407–1412
  23. Gibbons RP , Cole BS , Richardson RG , et al.  Adjuvant radiotherapy following radical prostatectomy: Results and complications . J Urol . 1986;135:65–68
  24. Thompson IM , Tangen CM , Paradelo J , et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial . JAMA . 2006;296:2329–2335
  25. Swanson GP , Thompson IM , Tangen C , et al.  Update of SWOG 8794: Adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival . Int J Radiat Oncol Biol Phys . 2008;72:S31
  26. Bolla M , van Poppel H , Collette L , et al.  Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911) . Lancet . 2005;366:572–578
  27. Ganswindt U , Stenzl A , Bamberg M , et al.  Adjuvant radiotherapy for patients with locally advanced prostate cancer—a new standard? . Eur Urol . 2008;54:528–542
  28. Dreicer R , Magi-Galluzzi C , Zhou M , et al.  Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer . Urology . 2004;63:1138–1142
  29. Febbo PG , Richie JP , George DJ , et al.  Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer . Clin Cancer Res . 2005;11:5233–5240
  30. Chi KN , Chin JL , Winquist E , et al.  Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer . J Urol . 2008;180:565–570 Discussion 570
  31. Konety BR , Eastham JA , Reuter VE , et al.  Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: Results of a phase I/II study . J Urol . 2004;171(2 Pt 1):709–713
  32. Clark PE , Peereboom DM , Dreicer R , et al.  Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer . Urology . 2001;57:281–285
  33. Pettaway CA , Pisters LL , Troncoso P , et al.  Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results . J Clin Oncol . 2000;18:1050–1057
  34. Prayer-Galetti T , Sacco E , Pagano F , et al.  Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer . BJU Int . 2007;100:274–280
  35. Hussain M , Smith DC , El-Rayes BF , et al.  Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer . Urology . 2003;61:774–780
  36. Eastham JA , Kelly WK , Grossfeld GD , et al.  Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone vs. estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease . Urology . 2003;62(Suppl 1):55–62
  37. Vuky J , Porter C , Isacson C , et al.  Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer . Cancer . 2009;115:184–191
  38. Mathew P , Pisters LL , Wood CG , et al.  Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer . J Urol . 2009;181:81–87 Discussion 87
  39. Wang J , Halford S , Rigg A , et al.  Adjuvant mitoxantrone chemotherapy in advanced prostate cancer . BJU Int . 2000;86:675–680
  40. Kibel AS , Rosenbaum E , Kattan MW , et al.  Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: A multi-institutional pilot study . J Urol . 2007;177:1777–1781
  41. Flaig TW , Tangen CM , Hussain MH , et al.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial . J Clin Oncol . 2008;26:1532–1536
  42. Zelefsky MJ , Fuks Z , Hunt M , et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer . J Urol . 2001;166:876–881
  43. Crook J , Ludgate C , Malone S , et al.  Final report of multicenter Canadian phase III randomized trial of 3 vs. 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer . Int J Radiat Oncol Biol Phys . 2009;73:327–333
  44. Lawton CA , Winter K , Murray K , et al.  Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate . Int J Radiat Oncol Biol Phys . 2001;49:937–946
  45. Pilepich MV , Winter K , John MJ , et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate . Int J Radiat Oncol Biol Phys . 2001;50:1243–1252
  46. Bolla M , Gonzalez D , Warde P , et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin . N Engl J Med . 1997;337:295–300
  47. Hanks GE , Pajak TF , Porter A , et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 . J Clin Oncol . 2003;21:3972–3978
  48. D'Amico AV , Manola J , Loffredo M , et al.  Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial . JAMA . 2004;292:821–827
  49. Roach M , Bae K , Speight J , et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 . J Clin Oncol . 2008;26:585–591
  50. Bolla M , Collette L , Van Tienhoven G , et al.  Ten-year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study . Int J Radiat Oncol Biol Phys . 2008;72: S30-S1
  51. Horwitz EM , Bae K , Hanks GE , et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer . J Clin Oncol . 2008;26:2497–2504
  52. Roach MR , Lu J , Pilepich MV , et al.  Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials . Int J Radiat Oncol Biol Phys . 2000;47:617–627
  53. Stock RG , Cahlon O , Cesaretti JA , et al.  Combined modality treatment in the management of high-risk prostate cancer . Int J Radiat Oncol Biol Phys . 2004;59:1352–1359
  54. Widmark A , Klepp O , Solberg A , et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial . Lancet . 2009;373:301–308
  55. Bianco FJ , Scardino PT , Stephenson AJ , et al.  Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy . Int J Radiat Oncol Biol Phys . 2005;62:448–453
  56. Lerner SE , Blute ML , Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer . J Urol . 1995;154:1103–1109
  57. Rosenthal SA , Bae K , Pienta KJ , et al.  Phase III multi-institutional trial of adjuvant chemotherapy with Paclitaxel, Estramustine, and Oral Etoposide combined with long-term androgen suppression therapy and radiotherapy vs. long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: Preliminary toxicity analysis of RTOG 99-02 . Int J Radiat Oncol Biol Phys . 2009;73:672–678
  58. Sandler HM , DeSilvio M , Pienta KJ , et al.   Preliminary analysis of RTOG 9902: Increased toxicity observed with the use of adjuvant chemotherapy . Am Soc Clin Oncol Prostate Cancer Symp. 2006; [Abstract 190]
  59. Kumar P , Perrotti M , Weiss R , et al.  Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate . J Clin Oncol . 2004;22:1909–1915
  60. Perrotti M , Doyle T , Kumar P , et al.  Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10) . Urol Oncol . 2008;26:276–280
  61. Ben-Josef E , Porter AT , Han S , et al.  Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostrate cancer: Feasibility and preliminary results . Int J Radiat Oncol Biol Phys . 2001;49:699–703
  62. Lin BJ , Chen KK , Chen MT , et al.  The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostate cancer . Urology . 1994;43:834–837
  63. Sasagawa I , Kubota Y , Nakada T , et al.  Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate . Int Urol Nephrol . 1998;30:745–753
  64. Medical Research Council Prostate Cancer Working Party Investigators Group . Immediate vs. deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial . Br J Urol . 1997;79:235–246
  65. Loblaw DA , Virgo KS , Nam R , et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology Proactive Guideline . J Clin Oncol . 2007;25:1596–1605
  66. Sharifi N , Gulley JL , Dahut WL . Androgen deprivation therapy for prostate cancer . JAMA . 2005;294:238–244
  67. Prostate Cancer Trialists' Collaborative Group . Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials . Lancet . 2000;355:1491–1498
  68. Usami M , Akaza H , Arai Y , et al.  Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) vs. LHRH-A monotherapy in advanced prostate cancer: Findings from a phase III randomized, double-blind, multicenter trial in Japanese patients . Prostate Cancer and Prostat Dis . 2007;10:194–201
  69. Akaza H , Hinotsu S , Usami M , et al.  Extended analyses: Combined androgen blockade therapy with bicalutamide vs. luteinizing hormone-releasing hormone agonist monotherapy in Japanese men with untreated advanced prostate cancer . J Clin Oncol . 2008;26:5063; [Abstract]
  70. Klotz L , Schellhammer P , Carroll K . A reassessment of the role of combined androgen blockade for advanced prostate cancer . Br J Urol . 2004;93:1177–1182
  71. Klotz L , Boccon-Gibod L , Shore ND , et al.  The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer . Br J Urol Int . 2008;102:1531–1538
  72. Gittelman M , Pommerville PJ , Persson BE , et al.  A 1-year, open-label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America . J Urol . 2008;180:1986–1992
  73. Tannock IF , Osoba D , Stockler MR , et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points . J Clin Oncol . 1996;14:1756–1764
  74. Kantoff PW , Halabi S , Conaway M , et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study . J Clin Oncol . 1999;17:2506–2513
  75. Petrylak DP , Tangen CM , Hussain MH , et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer . N Engl J Med . 2004;351:1513–1520
  76. Tannock IF , de Wit R , Berry WR , et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer . N Engl J Med . 2004;351:1502–1512
  77. Berthold DR , Pond GR , Soban F , et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study . J Clin Oncol . 2008;26:242–245
  78. Attard G , Reid AH , Yap TA , et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven . J Clin Oncol . 2008;26:4563–4571
  79. Figg WD , Hussain MH , Gulley JL , et al.  A double-blind randomized crossover crossover study of oral thalidomide vs. placebo for androgen dependent prostate cancer treated with intermittent androgen ablation . J Urol . 2009;181:1104–1113

PII: S1078-1439(09)00283-X

doi: 10.1016/j.urolonc.2009.09.002

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 3-15 , January 2012

Article Tools